197 related articles for article (PubMed ID: 29614442)
81. Frequency of actionable germline pathogenic variants identified through tumor next-generation sequencing in a gynecologic cancer cohort.
Karpel H; Manderski E; Pothuri B
Int J Gynecol Cancer; 2023 Jul; 33(7):1044-1050. PubMed ID: 36889816
[TBL] [Abstract][Full Text] [Related]
82. Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing.
Cheng DT; Prasad M; Chekaluk Y; Benayed R; Sadowska J; Zehir A; Syed A; Wang YE; Somar J; Li Y; Yelskaya Z; Wong D; Robson ME; Offit K; Berger MF; Nafa K; Ladanyi M; Zhang L
BMC Med Genomics; 2017 May; 10(1):33. PubMed ID: 28526081
[TBL] [Abstract][Full Text] [Related]
83. Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study.
Casula M; Paliogiannis P; Ayala F; De Giorgi V; Stanganelli I; Mandalà M; Colombino M; Manca A; Sini MC; Caracò C; Ascierto PA; Satta RR; ; Lissia A; Cossu A; Palmieri G;
BMC Cancer; 2019 Aug; 19(1):772. PubMed ID: 31382929
[TBL] [Abstract][Full Text] [Related]
84. Cancer surveillance and distress among adult pathogenic TP53 germline variant carriers in Germany: A multicenter feasibility and acceptance survey.
Rippinger N; Fischer C; Haun MW; Rhiem K; Grill S; Kiechle M; Cremer FW; Kast K; Nguyen HP; Ditsch N; Kratz CP; Vogel J; Speiser D; Hettmer S; Glimm H; Fröhling S; Jäger D; Seitz S; Hahne A; Maatouk I; Sutter C; Schmutzler RK; Dikow N; Schott S
Cancer; 2020 Sep; 126(17):4032-4041. PubMed ID: 32557628
[TBL] [Abstract][Full Text] [Related]
85. Pathogenic Variants in Adult-Onset Cancer Predisposition Genes in Pediatric Cancer: Prevalence and Impact on Tumor Molecular Features and Clinical Management.
McGee RB; Oak N; Harrison L; Xu K; Nuccio R; Blake AK; Mostafavi R; Lewis S; Taylor LM; Kubal M; Ouma A; Hines-Dowell SJ; Cheng C; Furtado LV; Nichols KE
Clin Cancer Res; 2023 Apr; 29(7):1243-1251. PubMed ID: 36693186
[TBL] [Abstract][Full Text] [Related]
86. Balancing Hope and Risk Among Adolescent and Young Adult Cancer Patients with Late-Stage Cancer: A Qualitative Interview Study.
Figueroa Gray M; Ludman EJ; Beatty T; Rosenberg AR; Wernli KJ
J Adolesc Young Adult Oncol; 2018 Dec; 7(6):673-680. PubMed ID: 30096254
[TBL] [Abstract][Full Text] [Related]
87. Landscape of somatic mutated genes and inherited susceptibility genes in gynecological cancer.
Watanabe T; Soeda S; Okoshi C; Fukuda T; Yasuda S; Fujimori K
J Obstet Gynaecol Res; 2023 Nov; 49(11):2629-2643. PubMed ID: 37632362
[TBL] [Abstract][Full Text] [Related]
88. Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management.
Shuch B; Vourganti S; Ricketts CJ; Middleton L; Peterson J; Merino MJ; Metwalli AR; Srinivasan R; Linehan WM
J Clin Oncol; 2014 Feb; 32(5):431-7. PubMed ID: 24378414
[TBL] [Abstract][Full Text] [Related]
89. "Somatic" Tumor Genomic Profiling and Potential Germline Implications: Ethical Considerations for Children with Cancer.
Knapp E
J Law Med Ethics; 2020 Dec; 48(4):778-783. PubMed ID: 33404327
[No Abstract] [Full Text] [Related]
90. Survival of European adolescents and young adults diagnosed with cancer in 2000-07: population-based data from EUROCARE-5.
Trama A; Botta L; Foschi R; Ferrari A; Stiller C; Desandes E; Maule MM; Merletti F; Gatta G;
Lancet Oncol; 2016 Jul; 17(7):896-906. PubMed ID: 27237614
[TBL] [Abstract][Full Text] [Related]
91. Accuracy of Hereditary Diffuse Gastric Cancer Testing Criteria and Outcomes in Patients With a Germline Mutation in CDH1.
van der Post RS; Vogelaar IP; Manders P; van der Kolk LE; Cats A; van Hest LP; Sijmons R; Aalfs CM; Ausems MG; Gómez García EB; Wagner A; Hes FJ; Arts N; Mensenkamp AR; van Krieken JH; Hoogerbrugge N; Ligtenberg MJ
Gastroenterology; 2015 Oct; 149(4):897-906.e19. PubMed ID: 26072394
[TBL] [Abstract][Full Text] [Related]
92. Investigation of clinically relevant germline variants detected by next-generation sequencing in patients with childhood cancer: a review of the literature.
Sylvester DE; Chen Y; Jamieson RV; Dalla-Pozza L; Byrne JA
J Med Genet; 2018 Dec; 55(12):785-793. PubMed ID: 30287599
[TBL] [Abstract][Full Text] [Related]
93. A novel combined resilience and advance care planning intervention for adolescents and young adults with advanced cancer: A feasibility and acceptability cohort study.
Fladeboe KM; O'Donnell MB; Barton KS; Bradford MC; Steineck A; Junkins CC; Yi-Frazier JP; Rosenberg AR
Cancer; 2021 Dec; 127(23):4504-4511. PubMed ID: 34358332
[TBL] [Abstract][Full Text] [Related]
94. Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer.
Weber-Lassalle N; Borde J; Weber-Lassalle K; Horváth J; Niederacher D; Arnold N; Kaulfuß S; Ernst C; Paul VG; Honisch E; Klaschik K; Volk AE; Kubisch C; Rapp S; Lichey N; Altmüller J; Lepkes L; Pohl-Rescigno E; Thiele H; Nürnberg P; Larsen M; Richters L; Rhiem K; Wappenschmidt B; Engel C; Meindl A; Schmutzler RK; Hahnen E; Hauke J
Breast Cancer Res; 2019 Apr; 21(1):55. PubMed ID: 31036035
[TBL] [Abstract][Full Text] [Related]
95. Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma.
Brand R; Borazanci E; Speare V; Dudley B; Karloski E; Peters MLB; Stobie L; Bahary N; Zeh H; Zureikat A; Hogg M; Lee K; Tsung A; Rhee J; Ohr J; Sun W; Lee J; Moser AJ; DeLeonardis K; Krejdovsky J; Dalton E; LaDuca H; Dolinsky J; Colvin A; Lim C; Black MH; Tung N
Cancer; 2018 Sep; 124(17):3520-3527. PubMed ID: 30067863
[TBL] [Abstract][Full Text] [Related]
96. Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil.
Palmero EI; Schüler-Faccini L; Caleffi M; Achatz MI; Olivier M; Martel-Planche G; Marcel V; Aguiar E; Giacomazzi J; Ewald IP; Giugliani R; Hainaut P; Ashton-Prolla P
Cancer Lett; 2008 Mar; 261(1):21-5. PubMed ID: 18248785
[TBL] [Abstract][Full Text] [Related]
97. Germline testing and genetic counseling in biliary tract cancer: an operative proposal to improve the state of art.
Rimini M; Presi S; Pipitone GB; Russo Raucci A; Ratti F; Della Corte A; Pedica F; Vanella G; Tonon G; Burgio V; Vitiello F; Rossari F; Amadeo E; Maria Giulia C; Pecciarini L; Arcidiacono PG; Falcinelli F; Cascinu S; De Cobelli F; Aldrighetti L; Patricelli MG; Carrera P; Casadei-Gardini A
Expert Rev Gastroenterol Hepatol; 2024; 18(4-5):141-146. PubMed ID: 38584510
[TBL] [Abstract][Full Text] [Related]
98. Prevalence of Adverse Event Reporting in Adolescents and Young Adults Enrolled in Cancer Clinical Trials.
Wayant C; Fitzgerald K; Hemmerich C; Geng Y; Freyer D; Roth M
JCO Oncol Pract; 2023 Nov; 19(11):1048-1052. PubMed ID: 37748116
[TBL] [Abstract][Full Text] [Related]
99. Incidental pathogenic germline alterations detected through liquid biopsy in patients with solid tumors: prevalence, clinical utility and implications.
Laguna JC; Pastor B; Nalda I; Hijazo-Pechero S; Teixido C; Potrony M; Puig-Butillé JA; Mezquita L
Br J Cancer; 2024 May; 130(9):1420-1431. PubMed ID: 38532104
[TBL] [Abstract][Full Text] [Related]
100. The Future of Parallel Tumor and Germline Genetic Testing: Is There a Role for All Patients With Cancer?
Liu YL; Stadler ZK
J Natl Compr Canc Netw; 2021 Jul; 19(7):871-878. PubMed ID: 34340209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
